Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Intrinsic Value
The intrinsic value of one Middle East Pharmaceutical Industries Company SJSC stock under the Base Case scenario is 79.53 SAR. Compared to the current market price of 121.2 SAR, Middle East Pharmaceutical Industries Company SJSC is Overvalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Middle East Pharmaceutical Industries Company SJSC
Fundamental Analysis


Revenue & Expenses Breakdown
Middle East Pharmaceutical Industries Company SJSC
Balance Sheet Decomposition
Middle East Pharmaceutical Industries Company SJSC
Current Assets | 323.8m |
Cash & Short-Term Investments | 13.8m |
Receivables | 175.8m |
Other Current Assets | 134.3m |
Non-Current Assets | 170.2m |
PP&E | 120.4m |
Intangibles | 49.9m |
Free Cash Flow Analysis
Middle East Pharmaceutical Industries Company SJSC
SAR | |
Free Cash Flow | SAR |
Earnings Waterfall
Middle East Pharmaceutical Industries Company SJSC
Revenue
|
596.5m
SAR
|
Cost of Revenue
|
-231.5m
SAR
|
Gross Profit
|
364.9m
SAR
|
Operating Expenses
|
-242.9m
SAR
|
Operating Income
|
122m
SAR
|
Other Expenses
|
-21.2m
SAR
|
Net Income
|
100.9m
SAR
|
Profitability Score
Profitability Due Diligence
Middle East Pharmaceutical Industries Company SJSC's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Score
Middle East Pharmaceutical Industries Company SJSC's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Middle East Pharmaceutical Industries Company SJSC's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Middle East Pharmaceutical Industries Company SJSC's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Middle East Pharmaceutical Industries Company SJSC
According to Wall Street analysts, the average 1-year price target for Middle East Pharmaceutical Industries Company SJSC is 133.62 SAR with a low forecast of 132.31 SAR and a high forecast of 137.55 SAR.
Dividends
Current shareholder yield for Middle East Pharmaceutical Industries Company SJSC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one Middle East Pharmaceutical Industries Company SJSC stock under the Base Case scenario is 79.53 SAR.
Compared to the current market price of 121.2 SAR, Middle East Pharmaceutical Industries Company SJSC is Overvalued by 34%.